Next-IO™ Anti-ROR1 × CD28 Bispecific Antibody Program

About This Program

This program aims to develop anti-ROR1 × CD28 therapeutic Bispecific Antibody for immuno-oncology.

T-cell-based cancer immunotherapy for some patients has demonstrated impressive achievements. In particular, by recognizing two different epitopes on T cells and cancer cells, Bispecific Antibody is attracting increasing attention as a novel strategy for cancer immunotherapy. Moreover, instead of focusing on traditional BiTEs, which rely on CD3 signaling without providing co-stimulation, the highlight of our program is to develop a CD28 Bispecific Antibody to focus on the co-stimulation pathway of T cell activation.

ROR1 × CD28

ROR1, a type I tyrosine kinase-like orphan receptor, is expressed by many cancers but not by normal postpartum tissues. ROR1 serves as a receptor for Wnt5a, which can be expressed by tumor cells or by accessory cells within tumor microenvironment.

CD28 is a differentiation antigen expressed on thymocytes and most mature T cells, including all CD4 T cells and CD8 T cells with cytolytic activity. At present, CD28, also called “T cell co-stimulation”, is at the forefront of the field. In addition to its costimulatory role, studies have demonstrated that CD28 ligation can enhance the production of various cytokines, such as IL-2, IL-4, and IL-10.

Published Data

To the best of our knowledge, there are few studies on anti-ROR1 × CD28 BITE. Further studies are required to dissect the efficacy, safety, and combination strategies. Here we show the published data about anti-ROR1 × CD28 Bispecific Antibody as a potential target for cancer immunotherapy.

  • ROR1/CD28 Bispecific Antibody significantly augmented the cytotoxic effects of ROR1/CD3 BiTE.
  • Anti-ROR1 × CD28 Bispecific Antibody Program

  • ROR1/CD28 Bispecific Antibody significantly augmented the cytotoxic effects of CD19/CD3 BiTE.
  • Anti-ROR1 × CD28 Bispecific Antibody Program

Indication

Based on the published data, we learn that the ROR1 is frequently expressed homogenously in multiple types of ovarian cancer, triple-negative breast cancer, and lung adenocarcinomas. Therefore, we intend to develop multiple programs for different indications (not limited to one specific tumor type), in which ROR1 is highly expressed.

Clinical Trials under Progress

Currently, there are still NO clinical studies on the novel ROR1 × CD28 BITE. While our program focuses on CD28 Bispecific Antibody antibodies, future efforts will develop simultaneous multiple interaction T-cell engaging (SMITE) bispecific pairs targeting other co-receptor signaling pathways. We are excited about this program and will do our best to make the dual targeting method clinically feasible.

Program Plan

Anti-ROR1 × CD28 Bispecific Antibody Program

With extensive experience in providing CRO services, we are confident about streamlined end-to-end program development. For each program, we are committed to developing the complete program to our partners from antibody discovery, engineering, optimization, to pre-clinical studies. Periodic progress will be delivered to our clients for timely communications.

Collaboration

Creative Biolabs is looking for potential partners (including major pharma or biotech firms) to develop the anti-ROR1 × CD28 Bispecific Antibody program. Our scientists are dedicated to bringing together years of value creation experience and research to explore strategic collaborations with our partner. This business strategy will enable both of us to proceed through IND and go beyond all stages of clinical trials.

If you are interested in our program, please feel free to contact us to learn more details about the cooperation. Looking forward to working with you in the near future.

Reference

  • Correnti C E., et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation[J]. Leukemia, 2018, 32(5): 1239.

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.